inaccuraci
earli
diagnosi
parkinson
diseas
pd
major
incent
studi
aim
identif
biomark
brainderiv
cerebrospin
fluid
csf
protein
potenti
biomark
consid
major
role
protein
play
pd
pathogenesi
review
discuss
current
hypothes
pathogenesi
pd
identifi
promis
candid
biomark
among
csf
protein
studi
far
list
potenti
marker
includ
protein
involv
variou
pathogenet
process
oxid
stress
protein
aggreg
list
undoubtedli
grow
near
futur
applic
csf
proteom
subsequ
valid
identifi
protein
probabl
singl
biomark
suffic
reach
high
sensit
specif
pd
pathogenet
heterogen
share
etiolog
factor
neurodegen
diseas
furthermor
identifi
candid
biomark
thoroughli
valid
implement
diagnost
aid
need
biomark
parkinson
diseas
diagnosi
parkinson
diseas
pd
current
mainli
base
clinic
featur
tolosa
et
al
ie
presenc
bradykinesia
combin
muscl
rigid
rest
tremor
postur
instabl
absenc
symptom
indic
atyp
parkinsonian
disord
support
find
includ
posit
effect
dopaminerg
medic
hugh
et
al
despit
clear
criteria
diagnos
pd
difficult
especi
earli
stage
particular
essenti
tremor
atyp
parkinsonian
syndrom
progress
supranuclear
palsi
psp
multipl
system
atrophi
msa
may
initi
mimic
pd
posit
predict
valu
final
clinic
diagnosi
idiopath
pd
made
movement
disord
specialist
demonstr
high
hugh
et
al
howev
studi
almost
one
third
clinic
diagnos
patient
parkinson
revis
averag
first
five
year
diseas
hugh
et
al
diagnost
accuraci
earli
stage
diseas
import
patient
moreov
facilit
evalu
futur
neuroprotect
therapi
improv
accuraci
earli
diagnosi
pd
biomark
urgent
need
biomark
defin
characterist
object
measur
indic
normal
pathogenet
process
respons
therapeut
intervent
exampl
biomark
pd
imag
marker
striatal
dopamin
transport
bind
measur
use
singl
photon
emiss
comput
tomographi
datspect
clinic
marker
diseas
includ
measur
nonmotor
function
sens
smell
autonom
function
protein
csf
andor
blood
may
also
serv
biomark
pd
yet
use
clinic
practic
ideal
biomark
sensit
reproduc
close
associ
diseas
process
easi
measur
inexpens
noninvas
thoroughli
valid
michel
et
al
biomark
fulfil
criteria
yet
identifi
pd
cerebrospin
fluid
csf
potenti
sourc
pd
biomark
live
patient
direct
contact
diseas
brain
specif
protein
play
major
role
pathogenesi
pd
brainderiv
csf
protein
therefor
promis
candid
biomark
howev
major
csf
protein
believ
origin
blood
rather
directli
surround
brain
tissu
bloodderiv
protein
enter
csf
choroid
plexu
along
flow
csf
ventricl
subarachnoid
space
huhmer
et
al
consequ
concentr
bloodderiv
protein
differ
ventricular
lumbar
csf
reiber
addit
bloodderiv
protein
brain
tissu
protein
contribut
csf
pool
recent
proteom
studi
report
almost
identifi
csf
protein
overlap
protein
detect
frontal
cortex
tissu
human
subject
pan
et
al
vice
versa
studi
protein
detect
frontal
cortex
tissu
detect
csf
pan
et
al
brain
tissu
protein
detect
csf
may
either
diffus
csf
exampl
membran
bound
mogi
et
al
may
intern
recycl
brain
tissu
form
insolubl
aggreg
level
may
low
detect
shi
et
al
total
protein
concentr
csf
obtain
lumbar
punctur
time
lower
blood
plasma
huhmer
et
al
normal
vari
mgl
rel
high
concentr
protein
blood
blood
contamin
lumbar
punctur
signific
effect
csf
proteom
hong
et
al
csf
protein
concentr
influenc
effect
circadian
rhythm
csf
secret
rate
maximum
h
time
higher
minimum
h
nilsson
et
al
preanalyt
factor
may
profoundli
influenc
protein
level
emphas
import
standard
protocol
csf
collect
teunissen
et
al
review
provid
overview
csf
protein
studi
pd
far
use
pathogenet
driven
approach
identifi
promis
diagnost
candid
biomark
among
better
understand
result
first
briefli
review
current
lead
hypothes
pd
pathogenesi
discuss
protein
play
role
pathogenet
process
promis
candid
csf
biomark
select
base
upon
relationship
pathogenesi
pd
differ
express
level
compar
control
csf
brain
tissu
discuss
challeng
encount
search
sensit
specif
biomark
give
recommend
futur
biomark
studi
pubm
search
done
march
parkinsonian
disord
mesh
parkinson
protein
mesh
enzym
coenzym
mesh
biolog
marker
mesh
cerebrospin
fluid
mesh
cerebrospin
fluid
subhead
addit
protein
name
enter
free
term
result
hit
paper
english
concern
human
subject
includ
studi
deal
comparison
pd
group
least
patient
control
group
consid
proteom
studi
differ
express
protein
valid
individu
sampl
studi
use
lumbar
csf
use
exclud
studi
ventricular
postmortem
csf
differ
protein
composit
ventricular
csf
compar
lumbar
csf
reiber
degrad
protein
due
postmortem
delay
respect
total
paper
fulfil
criteria
protein
includ
studi
classifi
accord
expect
function
relationship
pd
pathogenesi
sever
protein
multipl
alleg
role
could
assign
multipl
group
therefor
simplifi
classif
assign
protein
group
expect
main
contribut
relationship
pd
pathogenesi
main
hypothes
pd
pathogenesi
fig
patholog
pd
character
presenc
lewi
bodi
lewi
neurit
well
loss
catecholaminerg
neuron
substantia
nigra
locu
ceruleu
lewi
bodi
contain
larg
varieti
aggreg
protein
includ
ubiquitin
postmortem
studi
identif
gene
mutat
associ
parkinson
led
increas
insight
process
protein
play
role
pd
pathogenesi
process
summar
follow
paragraph
alreadi
eighti
nineti
centuri
mitochondri
dysfunct
implic
pd
pathogenesi
reduct
mitochondri
complex
activ
substantia
nigra
pd
patient
compar
control
schapira
et
al
realis
metabolit
mptp
exhibit
effect
interfer
mitochondri
electron
transport
chain
inhibit
mitochondri
complex
tipton
singer
could
caus
parkinson
develop
mptp
anim
model
pd
stress
role
mitochondri
dysfunct
mitochondri
complex
also
shown
inhibit
pesticid
rotenon
chronic
exposur
pesticid
result
symptom
resembl
parkinson
diseas
betarbet
et
al
furthermor
alter
level
mitochondriarel
protein
prohibitin
atp
synthas
superoxid
dismutas
demonstr
substantia
nigra
frontal
cortex
tissu
pd
patient
compar
control
ferrer
et
al
moreov
protein
product
mani
gene
associ
monogenet
form
parkinson
includ
parkin
implic
mitochondri
dysfunct
oxid
stress
lin
beal
loss
mitochondri
function
like
play
major
role
apoptosismedi
cell
death
via
releas
proapoptot
protein
like
cytochrom
c
second
messeng
mitochondri
activ
caspas
smac
lin
beal
reduc
atp
format
oxid
phosphoryl
moreov
dysfunct
mitochondria
lead
increas
oxygen
free
radic
consequ
increas
oxid
stress
schapira
inde
substantia
nigra
pd
patient
increas
amount
oxid
modifi
protein
observ
oxid
modifi
choi
et
al
nitrat
giasson
et
al
addit
increas
level
oxid
modifi
protein
alter
antioxid
protect
system
notabl
reduc
level
antioxid
glutathion
gsh
identifi
substantia
nigra
pd
patient
compar
control
sian
et
al
impair
protein
degrad
system
also
implic
pathogenesi
pd
system
includ
lysosom
degrad
pathway
ubiquitinproteasom
system
involv
degrad
misfold
mutant
denatur
otherwis
damag
protein
betarbet
et
al
lysosom
degrad
pathway
exampl
concern
degrad
oligomer
intermedi
lee
et
al
oligomer
intermedi
consid
toxic
form
caus
cellular
dysfunct
cell
death
elagnaf
et
al
involv
lysosom
degrad
pathway
pathogenesi
pd
support
alter
glucocerebrosidas
gene
sequenc
lysosom
enzym
postmortem
brain
tissu
pd
patient
lwin
et
al
twelv
pd
patient
mutat
gene
compar
none
control
subject
mutat
ubiquitinproteasom
system
system
label
protein
ubiquitin
guid
proteasom
degrad
also
result
parkinson
schapira
ubiquitin
depend
proteolyt
pathway
affect
patient
mutat
ubiquitin
carboxyltermin
esteras
gene
mutat
report
two
german
sibl
leroy
et
al
patient
parkin
mutat
account
almost
famili
youngonset
pd
luck
et
al
product
misfold
mutant
denatur
otherwis
damag
protein
impair
degrad
result
accumul
aggreg
protein
format
lewi
bodi
lewi
neurit
highli
preval
protein
lewi
type
patholog
protein
normal
present
presynapt
termin
neuron
point
mutat
duplic
triplic
gene
associ
hereditari
form
pd
polymeropoulo
et
al
kruger
et
al
zarranz
et
al
chartierharlin
et
al
singleton
et
al
present
monomer
form
although
trimer
may
also
present
physiolog
condit
leng
et
al
pd
synucleinopathi
monomer
aggreg
insolubl
fibril
intermedi
stage
format
aggreg
solubl
oligom
subsequ
form
protofibril
elagnaf
et
al
intermedi
consid
toxic
form
elagnaf
et
al
schapira
kazantsev
kolchinski
sever
factor
facilit
fibril
format
subsequ
aggreg
exampl
point
mutat
gene
phosphoryl
decreas
ph
increas
temperatur
presenc
metal
ion
small
charg
molecul
review
uverski
addit
aggreg
induc
protein
tissu
transglutaminas
tissu
transglutaminas
may
contribut
format
lewi
bodi
crosslink
protein
junn
et
al
recent
proteom
analysi
reveal
addit
mani
protein
present
lewi
bodi
includ
sever
kinas
ligas
protein
involv
protein
fold
membran
traffick
oxid
stress
xia
et
al
substantia
nigra
pd
patient
inflamm
repeatedli
demonstr
compris
microgli
activ
astrogliosi
lymphocyt
infiltr
hirsch
hunot
increas
level
interleukin
mogi
et
al
alter
growth
factor
level
parain
et
al
mogi
et
al
substantia
nigra
striatum
pd
patient
molecular
indic
inflamm
glial
involv
hypothes
inflammatori
chang
contribut
cascad
event
lead
neurodegener
henc
diseas
progress
hirsch
hunot
howev
inflamm
may
also
respons
neurodegen
process
support
contributori
role
inflamm
pd
pathogenesi
relationship
polymorph
neuroinflamm
associ
gene
tumor
necrosi
factoralpha
risk
pd
hirsch
hunot
well
protect
effect
nonsteroid
anti
inflammatori
drug
nsaid
chen
et
al
howev
neuroinflammatori
process
specif
pd
also
observ
neurodegen
disord
associ
parkinson
psp
msa
mcgeer
mcgeer
sakurai
et
al
apoptosismedi
cell
death
also
put
forward
possibl
pathogenet
factor
pd
mochizuki
et
al
histochem
detect
apoptosi
midbrain
pd
patient
compar
control
subject
mochizuki
et
al
furthermor
concentr
antiapoptot
protein
yuan
yankner
compensatorili
increas
nigrostriat
dopaminerg
neuron
pd
patient
compar
control
mogi
et
al
also
solubl
fa
apoptosissign
receptor
molecul
annexin
v
play
role
apoptot
cell
death
necrosi
increas
substantia
nigra
pd
suggest
role
apoptosi
pd
pathogenesi
mogi
et
al
werner
et
al
fact
mutat
apoptosi
relat
gene
demonstr
pd
patient
strauss
et
al
strengthen
likelihood
involv
apoptosi
pathogenesi
pd
gene
encod
serin
proteas
mitochondri
protein
degrad
apoptosi
inhibitor
insid
mitochondria
promot
apoptosi
cytosol
lin
beal
tabl
studi
investig
csf
level
mitochondriarel
antioxid
yield
conflict
result
waragai
et
al
report
increas
level
pd
patient
compar
nonpd
control
especi
earli
stage
pd
waragai
et
al
recent
studi
howev
report
decreas
level
csf
pd
patient
compar
alzheim
diseas
patient
control
discrep
result
two
studi
ascrib
either
crossreact
molecul
detect
elisa
techniqu
limit
elisa
kit
degre
blood
contamin
hong
et
al
chang
level
oxid
stress
relat
protein
also
demonstr
csf
pd
patient
exampl
concentr
nitrat
manganes
superoxid
dismutas
mnsod
assum
marker
peroxynitritemedi
oxid
stress
increas
group
pd
patient
compar
control
aoyama
et
al
antioxid
activ
cuzndepend
superoxid
dismutas
reduc
csf
pd
alzheim
diseas
ad
huntington
diseas
hd
amyotroph
later
sclerosi
al
patient
boll
et
al
oxid
modifi
form
protein
increas
csf
pd
patient
compar
control
guo
et
al
ceruloplasmin
transferrin
antioxid
protein
studi
csf
abdi
et
al
boll
et
al
loeffler
et
al
van
kamp
et
al
boll
et
al
ferroxidas
enzym
ceruloplasmin
convert
transport
transferrin
togeth
limit
gener
toxic
hydroxyl
radic
loeffler
et
al
csf
transferrin
level
pd
patient
differ
csf
level
control
loeffler
et
al
van
kamp
et
al
ferroxidas
activ
csf
ceruloplasmin
level
reduc
dexter
et
al
kuiper
et
al
pall
et
al
transferrin
loeffler
et
al
van
kamp
et
al
rota
et
al
detect
basic
fibroblast
growth
factor
bfgf
detect
transform
growth
factoralpha
detect
epiderm
growth
factor
egf
detect
elizan
et
al
slightli
detect
marttila
et
al
antibodi
elizan
et
al
slightli
detect
marttila
et
al
antibodi
cmv
elizan
et
al
slightli
detect
marttila
et
al
pd
boll
et
al
boll
et
al
ceruloplasmin
sensit
specif
roc
curv
area
roc
curv
abdi
et
al
csf
pd
patient
activ
three
five
studi
lysosom
enzym
reduc
p
b
n
p
n
pn
balducci
et
al
best
knowledg
none
protein
directli
involv
ubiquitinproteasom
system
studi
csf
pd
biomark
purpos
alphasynuclein
main
compon
lewi
bodi
detect
csf
blood
appli
elisa
detect
total
borghi
et
al
lee
et
al
li
et
al
mollenhau
et
al
ohrfelt
et
al
tokuda
et
al
hong
et
al
plasma
recent
csf
specif
elisa
oligomer
form
develop
maetzler
et
al
oligomer
form
increas
csf
patient
lewi
bodi
diseas
pd
dlb
combin
compar
nonlewi
bodi
diseas
subject
control
tauopathi
maetzler
et
al
howev
result
includ
tabl
level
oligomer
pd
patient
report
separ
maetzler
et
al
total
csf
either
decreas
tokuda
et
al
mollenhau
et
al
hong
et
al
unchang
borghi
et
al
ohrfelt
et
al
pd
patient
compar
control
largest
studi
csf
level
recent
publish
hong
et
al
observ
reduc
level
pd
patient
compar
alzheim
diseas
patient
control
control
blood
contamin
hong
et
al
associ
level
diseas
sever
found
studi
contrast
result
previou
studi
show
invers
correl
diseas
sever
tokuda
et
al
tissu
transglutaminas
may
contribut
aggreg
promot
crosslink
junn
et
al
increas
almost
tenfold
pd
patient
comparison
control
although
overlap
control
certain
pd
patient
indic
low
sensit
potenti
diagnost
marker
verm
et
al
osteopontin
level
one
sever
protein
express
lewi
bodi
also
increas
csf
pd
patient
compar
control
maetzler
et
al
protein
may
involv
mani
pathogenet
mechan
includ
oxid
stress
mitochondri
impair
apoptosi
cytokin
regul
protein
detect
lewi
bodi
neurofila
hill
et
al
part
cytoskeleton
level
neurofila
heavi
chain
light
isoform
similar
csf
pd
patient
compar
control
abdo
et
al
brettschneid
et
al
holmberg
et
al
howev
neurofila
level
increas
csf
psp
msa
patient
compar
pd
patient
observ
interpret
reflect
progress
natur
diseas
process
diseas
abdo
et
al
brettschneid
et
al
holmberg
et
al
involv
inflammatori
mechan
pd
support
increas
csf
level
interleukin
includ
blumdegen
et
al
muller
et
al
zhang
et
al
decreas
level
compon
complement
system
complement
protein
factor
b
finehout
et
al
guo
et
al
pd
patient
decreas
level
compon
complement
system
could
indic
overactiv
complement
system
subsequ
deplet
furthermor
growth
factor
brainderiv
neurotroph
factor
bdnf
growth
associ
protein
insulinlik
growth
striatal
deriv
neurotroph
factor
report
differ
express
although
result
conflict
bdnf
carvey
et
al
sjogren
et
al
zhang
et
al
salehi
mashayekhi
mashayekhi
et
al
csf
studi
also
link
pd
gener
autoantibodi
increas
viral
antibodi
level
fazzini
et
al
gao
et
al
marttila
et
al
although
intrathec
antibodi
product
could
demonstr
marttila
et
al
apoptosissign
molecul
sfa
protein
increas
nigrostriat
tissu
pd
patient
detect
csf
use
twosit
sandwich
enzymelink
immunosorb
assay
mogi
et
al
b
may
detect
membran
bound
mogi
et
al
csf
level
annexin
v
adher
die
cell
decreas
pd
patient
possibl
due
increas
usag
verm
et
al
csf
protein
relat
describ
pd
pathogenet
mechan
tabl
alzheim
diseas
associ
protein
alzheim
diseasetyp
neuropatholog
chang
common
pd
patient
mattila
et
al
three
csf
marker
studi
inflamm
glial
activ
unclassifi
immun
system
glial
protein
glial
fibrillari
acid
protein
gfap
holmberg
et
al
constantinescu
et
al
matrix
metalloproteinas
mmp
indirectli
relat
immun
system
lorenzl
et
al
matrix
metalloproteinas
mmp
indirectli
relat
immun
system
lorenzl
et
al
tissu
inhibitor
mmp
indirectli
relat
immun
system
lorenzl
et
al
tissu
inhibitor
mmp
indirectli
relat
immun
system
lorenzl
et
al
csfserum
ratio
albumin
indirectli
relat
immun
system
note
classif
protein
group
simplifi
sever
protein
involv
multipl
pathway
assign
multipl
group
indic
elev
level
pd
compar
control
patient
indic
decreas
level
pd
compar
control
patient
indic
differ
pd
control
patient
ad
name
tau
phosphoryl
tau
beta
repeatedli
studi
pd
pd
beta
incident
found
decreas
bibl
et
al
compta
et
al
parnetti
et
al
sjogren
et
al
gener
appear
unchang
compar
control
holmberg
et
al
lin
et
al
mollenhau
et
al
sjogren
et
al
verbeek
et
al
zhang
et
al
kanemaru
et
al
differ
csf
tau
phosphoryl
tau
level
pd
control
demonstr
twice
abdo
et
al
compta
et
al
ad
associ
protein
tau
arai
et
al
bibl
et
al
blennow
et
al
jansen
et
al
kahl
et
al
lin
et
al
molina
et
al
mollenhau
et
al
paraskeva
et
al
sjogren
et
al
sjogren
et
al
sjogren
et
al
zhang
et
al
parnetti
et
al
borroni
et
al
kanemaru
et
al
borroni
et
al
compta
et
al
abdo
et
al
compta
et
al
pdd
phosphotau
blennow
et
al
lin
et
al
sjogren
et
al
sjogren
et
al
parnetti
et
al
borroni
et
al
borroni
et
al
compta
et
al
compta
et
al
pdd
beta
amyloid
specifi
van
gool
et
al
beta
holmberg
et
al
lin
et
al
mollenhau
et
al
sjogren
et
al
verbeek
et
al
zhang
et
al
kanemaru
et
al
compta
et
al
bibl
et
al
sjogren
et
al
parnetti
et
al
compta
et
al
pdd
compta
et
al
beta
amyloid
precursor
protein
henriksson
et
al
thread
protein
de
la
mont
et
al
kahl
et
al
mont
et
al
yamada
et
al
strittmatt
et
al
somatostatinlik
immunoreact
hartikainen
et
al
poew
et
al
volic
et
al
espino
et
al
dupont
et
al
jolkkonen
et
al
strittmatt
et
al
strittmatt
cramer
unger
et
al
strittmatt
et
al
strittmatt
et
al
desalasomatostatin
strittmatt
et
al
corticotropinreleas
hormon
crh
suemaru
et
al
arginin
vasopressin
olsson
et
al
sundquist
et
al
neurokinin
galard
et
al
homocarnosin
betalipotropin
nappi
et
al
adrenocorticotrop
hormon
acth
nappi
et
al
unclassifi
protein
total
protein
concentr
zubenko
et
al
hartikainen
et
al
acetylcholinesteras
immunoreact
kone
et
al
pd
nondement
kone
et
al
pdd
acetylcholinesteras
activ
hartikainen
et
al
jolkkonen
et
al
kone
et
al
manyam
et
al
ruberg
et
al
zubenko
et
al
kone
et
al
pdd
butyrylcholinesteras
activ
ruberg
et
al
sirvio
et
al
maetzler
et
al
dopaminebetahydroxylas
activ
hartikainen
et
al
angiotensinconvert
enzym
ace
kone
et
al
zubenko
et
al
zubenko
et
al
angiotensinconvert
enzym
ace
activ
kone
et
al
treat
pd
patient
kone
et
al
untreat
pd
patient
zubenko
et
al
zubenko
et
al
shikimi
et
al
note
classif
protein
group
simplifi
sever
protein
involv
multipl
pathway
assign
multipl
group
indic
elev
level
pd
compar
control
patient
indic
decreas
level
pd
compar
control
patient
indic
differ
pd
control
patient
mont
et
al
yamada
et
al
lidstrom
et
al
except
apo
apoaii
protein
zhang
et
al
guo
et
al
differ
compar
control
recent
compta
et
al
report
dissimilar
level
tau
phosphoryl
tau
beta
could
demonstr
subgroup
pd
patient
name
patient
diagnos
parkinson
diseas
relat
dementia
pdd
compta
et
al
explan
find
might
underli
adpatholog
pdd
respons
differ
level
ad
associ
protein
csf
neuropeptid
studi
extens
eighti
nineti
last
centuri
neuropeptid
short
polym
amino
acid
secret
neuron
interneuron
commun
purpos
may
modul
receptor
sensit
interact
neurotransmitt
strittmatt
et
al
sever
neuropeptid
decreas
csf
pd
patient
compar
control
includ
metenkephalin
fischer
yaksh
et
al
lotstra
et
al
arginin
vasopressin
olsson
et
al
sundquist
et
al
potenti
explan
decreas
cell
death
specif
neuron
suppress
secretori
activ
strittmatt
et
al
cell
death
may
hand
result
increas
level
neuropeptid
releas
peptid
damag
brain
tissu
espino
et
al
rais
csf
peptid
level
demonstr
diazepam
bind
inhibitor
dbi
ferrero
et
al
b
desalasomatostatin
strittmatt
et
al
sever
neuropeptid
report
result
neuropeptid
studi
led
conflict
data
dupont
et
al
espino
et
al
jolkkonen
et
al
strittmatt
et
al
strittmatt
cramer
unger
et
al
potenti
pd
candid
biomark
tabl
identifi
potenti
pd
candid
biomark
chose
use
follow
criteria
protein
differ
express
pd
patient
compar
control
affect
brain
tissu
csf
protein
bear
relationship
pathogenet
mechan
involv
pd
state
sensit
specif
biomark
pd
within
group
pathogenesi
relat
protein
tabl
list
protein
fulfil
criteria
provid
direct
chang
protein
level
csf
affect
brain
tissu
list
includ
oxid
stress
relat
protein
ceruloplasmin
oxid
modifi
lysosom
enzym
betaglucocerebrosidas
protein
relat
protein
aggreg
lewi
bodi
format
tissu
transglutaminas
osteopontin
furthermor
number
protein
involv
inflamm
glial
activ
candid
pd
biomark
bdnf
tissu
inhibitor
matrix
tumor
necrosi
factoralpha
direct
chang
sever
studi
protein
csf
brain
tissu
chang
opposit
direct
observ
number
protein
includ
ceruloplasmin
osteopontin
may
result
activ
transport
ie
secret
extract
tissu
csf
conflict
result
among
studi
csf
protein
might
result
differ
appli
assay
andor
signific
effect
blood
contamin
report
csf
level
hong
et
al
list
still
limit
undoubtedli
grow
near
futur
applic
proteom
subsequ
valid
identifi
protein
furthermor
addit
protein
might
result
identif
new
pathogenet
process
involv
pd
import
stress
candidaci
coupl
select
potenti
biomark
base
singl
find
strong
need
valid
potenti
csf
biomark
preferenti
patholog
confirm
cohort
account
interlaboratori
variabl
multipl
center
rel
contribut
variou
mechan
mitochondri
dysfunct
oxid
stress
impair
protein
degrad
etcetera
pathogenesi
may
vari
pd
patient
heterogen
pathogenesi
pd
make
like
tabl
biomark
candid
protein
relat
pathogenesi
pd
differ
express
pd
patient
compar
control
csf
brain
tissu
mitochondri
dysfunct
increas
oxid
stress
ceruloplasmin
ferroxidas
loeffler
et
al
abdi
et
al
loeffler
et
al
kumaran
et
al
waragai
et
al
hong
et
al
oxid
modifi
superoxid
dismutas
choi
et
al
guo
et
al
impair
protein
degrad
betaglucocerebrosidas
activ
alter
glucocerebrosidas
gene
sequenc
lwin
et
al
balducci
et
al
protein
aggreg
lewi
bodi
format
present
lewi
bodi
sdssolubl
tong
et
al
borghi
et
al
ohrfelt
et
al
iczkiewicz
et
al
present
lewi
bodi
maetzler
et
al
maetzler
et
al
inflamm
glial
activ
interleukin
mogi
et
al
pirttila
et
al
blumdegen
et
al
detect
mogi
et
al
blumdegen
et
al
muller
et
al
detect
brainderiv
neurotroph
factor
bdnf
murer
et
al
parain
et
al
zhang
et
al
salehi
mashayekhi
tissu
inhibitor
mmp
lorenzl
et
al
lorenzl
et
al
tumor
necrosi
factoralpha
mogi
et
al
nagatsu
et
al
le
et
al
mogi
et
al
mogi
et
al
zhang
et
al
detect
sd
sodium
dodecyl
sulfat
indic
elev
level
pd
compar
control
patient
indic
decreas
level
pd
compar
control
patient
indic
differ
pd
control
patient
combin
protein
repres
differ
pathogenet
process
need
accomplish
suffici
high
degre
sensit
combin
candid
biomark
list
tabl
may
capabl
reach
requir
sensit
may
differenti
pd
patient
earli
stage
diseas
healthi
individu
clinic
set
also
essenti
differenti
pd
neurodegen
disord
particular
msa
psp
earli
stage
sever
protein
list
tabl
studi
neurodegen
disord
although
major
protein
studi
atyp
parkinsonian
syndrom
psp
msa
clear
sever
protein
specif
pd
lack
specif
appli
protein
associ
differ
pathogenet
process
vari
increas
oxid
stress
inflamm
exampl
csf
level
glucocerebrosidas
activ
decreas
pd
also
decreas
dementia
lewi
bodi
dlb
patient
csf
level
yet
evalu
neurodegen
diseas
multipl
sclerosi
patient
howev
csf
level
significantli
higher
comparison
control
hirotani
et
al
inflammatori
protein
seem
least
specif
pathogenet
group
inflammatori
cytokin
level
increas
csf
patient
small
infarct
ad
blumdegen
et
al
wherea
increas
csf
patient
diagnos
psp
ad
huntington
diseas
amyotroph
later
sclerosi
lorenzl
et
al
addit
bdnf
increas
csf
ad
patient
blumdegen
et
al
tarkowski
et
al
zhang
et
al
like
pd
patient
lack
specif
sever
candid
biomark
explain
fact
neurodegen
disord
pd
msa
psp
overlap
clinic
also
share
neuropatholog
characterist
hypothes
pathogenet
mechan
much
like
pd
msa
psp
neuropatholog
character
presenc
protein
aggreg
msa
aggreg
princip
compos
locat
oligodendrogli
cell
wakabayashi
et
al
psp
hyperphosphoryl
tau
accumul
neuron
hauw
et
al
protein
involv
apoptosi
antioxid
protein
also
detect
postmortem
aggreg
msa
review
wen
et
al
psp
pd
kinas
mitochondri
dysfunct
chronic
inflamm
may
play
import
role
pathogenesi
ludolph
et
al
neuropatholog
immunohistochemistri
present
gold
standard
detect
pd
patholog
protein
could
highli
effect
pd
biomark
theori
could
differenti
synucleinopathi
pd
msa
dlb
tauopathi
like
psp
disappoint
result
total
could
relat
studi
form
protein
quit
possibl
toxic
intermedi
alreadi
found
increas
plasma
pd
patient
compar
control
csf
combin
pddlb
group
compar
nonlewi
bodi
diseas
subject
maetzler
et
al
promis
target
rate
progress
differ
neurodegen
disord
form
second
clue
select
specif
pd
biomark
msa
psp
tend
progress
rapidli
pd
higher
rate
cell
death
consequ
increas
releas
cellular
protein
csf
exampl
neurofila
protein
cytoskelet
protein
also
present
lewi
bodi
hill
et
al
increas
csf
msa
psp
corticobas
degener
cbd
patient
compar
pd
patient
abdo
et
al
brettschneid
et
al
holmberg
et
al
may
use
differenti
atyp
parkinsonian
disord
pd
earli
stage
thirdli
quit
possibl
specif
csf
biomark
pd
yet
identifi
major
review
studi
base
hypothesi
driven
research
anticip
come
year
proteom
analysi
csf
techniqu
enabl
largescal
unbias
identif
protein
shi
et
al
offer
great
opportun
identif
novel
specif
biomark
candid
particular
proteom
studi
would
includ
addit
diagnost
group
msa
psp
altogeth
combin
biomark
probabl
requir
reach
suffici
high
sensit
specif
propos
select
biomark
differ
pathogenet
process
account
pathogenet
heterogen
diseas
exampl
addit
biomark
differenti
pd
atyp
parkinsonian
disord
exampl
neurofila
perspect
combin
marker
promis
biomark
studi
multipl
marker
perform
zhang
et
al
combin
eight
protein
deriv
use
proteom
csf
analysi
subsequ
antibodi
base
valid
combin
protein
agre
expert
diagnos
pd
patient
control
subject
ad
patient
addit
csf
protein
biochem
marker
like
oxid
stress
marker
deoxyguanosin
gmitterova
et
al
isob
et
al
nonbiochem
marker
like
dopamin
transport
singl
photon
emiss
comput
tomographi
datspect
mri
olfactori
test
neuropsycholog
evalu
graeber
help
increas
sensit
specif
final
biomark
may
improv
accuraci
earli
pd
diagnosi
may
also
suitabl
effect
monitor
diseas
progress
marker
diseas
progress
crucial
evalu
neuromodulatori
neuroprotect
therapi
maetzler
et
al
studi
followup
measur
recent
publish
studi
constantinescu
et
al
requir
purpos
chang
level
sever
studi
csf
protein
pd
patient
support
hypothes
pathogenet
mechan
includ
mitochondri
dysfunct
oxid
stress
protein
degrad
involv
lysosom
pathway
inflammatori
process
glial
cell
activ
cell
death
howev
sensit
specif
thoroughli
valid
diagnost
csf
marker
pd
yet
identifi
protein
relat
pathogenesi
addit
differ
express
pd
patient
compar
control
affect
brain
tissu
csf
antioxid
crosslink
protein
tissu
transglutaminas
may
potenti
candid
biomark
howev
specif
candid
biomark
may
low
due
heterogen
diseas
patholog
patholog
overlap
neurodegen
disord
specif
sensit
may
increas
select
set
csf
biomark
combin
nonbiochem
marker
exampl
brain
imag
olfactori
test
unbias
discoveri
use
mass
spectrometri
base
csf
proteom
includ
pd
patient
sever
diagnost
group
might
yield
addit
pdspecif
biomark
proteom
find
need
translat
develop
conveni
multiparamet
test
largescal
analysi
broad
applic
among
laboratori
anoth
import
element
still
lack
reproduct
find
largescal
valid
candid
biomark
preferenti
neuropatholog
confirm
pd
patient
access
bodi
fluid
blood
urin
fluid
brain
tissu
protein
may
present
low
concentr
valid
patient
group
differ
diseas
stage
well
longitudin
studi
may
reveal
marker
reflect
predict
diseas
progress
addit
valid
step
essenti
enabl
clinic
applic
csf
biomark
pd
